AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16467233 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary modification intervention
Number of subjects: 48835
Study 16467233 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 48835
Study 15475128 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat tibial insert with retention of the posterior cruciate ligament
Number of subjects: 28
Study 15475128 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave tibial insert with retention of the posterior cruciate ligament
Number of subjects: 28
Study 15475128 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave tibial component with resection of the posterior cruciate ligament
Number of subjects: 28
Study 15475128 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized tibial component with resection of the posterior cruciate ligament
Number of subjects: 28
Study 15475128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 11318768 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg daily if creatinine < 150 micromol l‐1 or 100 mg if creatinine > 150 micromol l‐1)
Number of subjects: 16
Study 11318768 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 16
Study 11318768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10481379 — intervention group
Group type: COMPARATOR
Intervention: Hyperthyroidism
Number of subjects: 10
Study 10481379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological euthyroidism
Number of subjects: 10
Study 10481379 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthyroidism after surgical treatment
Number of subjects: 10
Study 7962578 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movement desensitization (EMD)
Number of subjects: 30
Study 7962578 — intervention group
Group type: COMPARATOR
Intervention: Finger tapping (control)
Number of subjects: 30
Study 3307897 — intervention group
Group type: EXPERIMENTAL
Intervention: Humphrey automated threshold perimetry (Program 30‐2)
Number of subjects: 25
Study 3307897 — intervention group
Group type: COMPARATOR
Intervention: Goldmann perimetry
Number of subjects: 25
Study 3307897 — intervention group
Group type: COMPARATOR
Intervention: Humphrey automated perimetry
Number of subjects: 25
Study 3307897 — intervention group
Group type: EXPERIMENTAL
Intervention: Humphrey automated perimetry (Program 30‐2)
Number of subjects: 25
Study 31272205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (endurance and resistance training with moderate intensity, at least three times per week for six months)
Number of subjects: 61
Study 31272205 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 61
Study 31272205 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 61
Study 27882653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunnybrook composite score at 1 month
Number of subjects: 743
Study 27882653 — intervention group
Group type: EXPERIMENTAL
Intervention: Symmetry of voluntary movement at 1 month
Number of subjects: 743
Study 27882653 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle eye closure and open-mouth smile
Number of subjects: 743
Study 27882653 — intervention group
Group type: EXPERIMENTAL
Intervention: Synkinesis frequency
Number of subjects: 743
Study 27882653 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe synkinesis
Number of subjects: 743
Study 27882653 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean synkinesis score
Number of subjects: 743
Study 25185932 — intervention group
Group type: COMPARATOR
Intervention: Calcium alginate
Number of subjects: 57
Study 25185932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofiber
Number of subjects: 57
Study 25185932 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam
Number of subjects: 57
Study 23741380 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 180
Study 23741380 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 21091548 — intervention group
Group type: COMPARATOR
Intervention: N-Bt diet
Number of subjects: 33
Study 21091548 — intervention group
Group type: COMPARATOR
Intervention: Bt diet
Number of subjects: 33
Study 21091548 — intervention group
Group type: COMPARATOR
Intervention: Control and N-Bt diet
Number of subjects: 33
Study 21091548 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 33
Study 18815144 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based diet and stress reduction
Number of subjects: 0
Study 16428337 — intervention group
Group type: EXPERIMENTAL
Intervention: LCA group (n = 36)
Number of subjects: 50
Study 16428337 — intervention group
Group type: COMPARATOR
Intervention: RCA group (n = 14)
Number of subjects: 50
Study 12636888 — intervention group
Group type: COMPARATOR
Intervention: 20 degrees C condition
Number of subjects: 34
Study 12636888 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 degrees C condition
Number of subjects: 34
Study 10618562 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate suture closure with the double-suture Prostar-Plus device
Number of subjects: 100
Study 10618562 — intervention group
Group type: COMPARATOR
Intervention: Delayed sheath removal with application of a c-clamp
Number of subjects: 100
Study 10618562 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 8738356 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite vibration composed of two 1/3 octave‐band vibrations
Number of subjects: 8
Study 8738356 — intervention group
Group type: COMPARATOR
Intervention: 1/3 octave‐band vibrations (63, 200, and 500 Hz)
Number of subjects: 8
Study 1574461 — intervention group
Group type: EXPERIMENTAL
Intervention: DRE with TRUS
Number of subjects: 0
Study 1574461 — intervention group
Group type: COMPARATOR
Intervention: No screening
Number of subjects: 0
Study 1574461 — intervention group
Group type: EXPERIMENTAL
Intervention: DRE with TRUS and PSA measurement if results are suspicious
Number of subjects: 0
Study 1574461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-screen PSA
Number of subjects: 0
Study 6373102 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (6 mg/sq m)
Number of subjects: 27
Study 6373102 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (1 mg/sq m)
Number of subjects: 27
Study 6373102 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (1 mg/sq m)
Number of subjects: 27
Study 31834923 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration of the Patient-Specific Functional Scale (PSFS)
Number of subjects: 74
Study 31834923 — intervention group
Group type: COMPARATOR
Intervention: In-person administration of the Patient-Specific Functional Scale (PSFS)
Number of subjects: 74
Study 29743962 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 80
Study 29743962 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (50 mg)
Number of subjects: 80
Study 25884637 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based 12-week physical activity intervention program
Number of subjects: 30
Study 25884637 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 30
Study 24002802 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor functional vision group (n=95)
Number of subjects: 576
Study 24002802 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional vision
Number of subjects: 576
Study 21310741 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation high-flux dialyser (Polynephron)
Number of subjects: 14
Study 21310741 — intervention group
Group type: COMPARATOR
Intervention: First-generation high-flux dialyser (DIAPES-HF800)
Number of subjects: 14
Study 21310741 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection dialysis strategy
Number of subjects: 14
Study 21310741 — intervention group
Group type: COMPARATOR
Intervention: Diffusion dialysis strategy
Number of subjects: 14
Study 19750873 — intervention group
Group type: EXPERIMENTAL
Intervention: Prismatic displacement adaptation with a concurrent cognitive task (serial subtractions of 7)
Number of subjects: 0
Study 19750873 — intervention group
Group type: EXPERIMENTAL
Intervention: Prismatic displacement adaptation with a concurrent cognitive task (repeating back tones)
Number of subjects: 0
Study 19750873 — intervention group
Group type: COMPARATOR
Intervention: Prismatic displacement adaptation without a concurrent cognitive task
Number of subjects: 0
Study 17578562 — intervention group
Group type: EXPERIMENTAL
Intervention: 17OHPC (250 mg intramuscular injections weekly from 16-20 weeks up to 36 weeks)
Number of subjects: 660
Study 17578562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660
Study 17578562 — intervention group
Group type: EXPERIMENTAL
Intervention: 17OHPC
Number of subjects: 660
Study 15565072 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 12
Study 15565072 — intervention group
Group type: EXPERIMENTAL
Intervention: White bagel
Number of subjects: 12
Study 15565072 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanuts
Number of subjects: 12
Study 15565072 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein bar
Number of subjects: 12
Study 15565072 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein drink
Number of subjects: 12
Study 11563245 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9822209 — intervention group
Group type: EXPERIMENTAL
Intervention: smiling scale/sensory instructions
Number of subjects: 100
Study 9822209 — intervention group
Group type: COMPARATOR
Intervention: neutral scale/sensory instructions
Number of subjects: 100
Study 9822209 — intervention group
Group type: EXPERIMENTAL
Intervention: smiling scale/affective instructions
Number of subjects: 100
Study 9400343 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 40
Study 9400343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1850282 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (NS)
Number of subjects: 4
Study 1850282 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's (LR)
Number of subjects: 4
Study 1850282 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline adjusted to pH 7.4 with sodium bicarbonate (NS + Bicarb)
Number of subjects: 4
Study 1850282 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Saline Solution Plus (BSS Plus)
Number of subjects: 4
Study 7067541 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural opiates
Number of subjects: 0
Study 7067541 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia
Number of subjects: 0
Study 7067541 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with local anesthetics (EPA)
Number of subjects: 0
Study 7067541 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative peridural opiates
Number of subjects: 0
Study 30098860 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance (BCM)
Number of subjects: 120
Study 30098860 — intervention group
Group type: COMPARATOR
Intervention: DEXA
Number of subjects: 120
Study 29024419 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiFix and multilayer compression therapy
Number of subjects: 109
Study 29024419 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care and multilayer compression therapy
Number of subjects: 109
Study 29024419 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiFix
Number of subjects: 109
Study 27588078 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment + oral administration of Jiawei Di Tan Tang
Number of subjects: 60
Study 27588078 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 60
Study 24827405 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 64
Study 24827405 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 64
Study 22568808 — intervention group
Group type: EXPERIMENTAL
Intervention: Roledumab (30-3000 μg i.v. and 300 μg i.m.)
Number of subjects: 46
Study 22568808 — intervention group
Group type: EXPERIMENTAL
Intervention: Roledumab (30-3000 μg i.v.)
Number of subjects: 46
Study 22568808 — intervention group
Group type: EXPERIMENTAL
Intervention: Roledumab (300 μg i.m.)
Number of subjects: 46
Study 22568808 — intervention group
Group type: EXPERIMENTAL
Intervention: Roledumab
Number of subjects: 46
Study 22568808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 21755798 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond MP Plus (light-cured)
Number of subjects: 60
Study 21755798 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond MP Plus (chemically-cured)
Number of subjects: 60
Study 21755798 — intervention group
Group type: EXPERIMENTAL
Intervention: Allbond 2 (light-cured)
Number of subjects: 60
Study 21755798 — intervention group
Group type: EXPERIMENTAL
Intervention: Allbond 2 (chemically-cured)
Number of subjects: 60
Study 21755798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (light-cured)
Number of subjects: 60
Study 21755798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.1 (chemically-cured)
Number of subjects: 60
Study 21755798 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-cured samples (group)
Number of subjects: 60
Study 21755798 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically-cured samples (group)
Number of subjects: 60
Study 18578856 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up by the district GP
Number of subjects: 170
Study 18578856 — intervention group
Group type: COMPARATOR
Intervention: Follow-up at the surgical outpatient clinic
Number of subjects: 170
Study 15904528 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care educational program
Number of subjects: 44
Study 15904528 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study 11932063 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA morphine 1 mg/cc plus naloxone 6 microg/cc
Number of subjects: 166
Study 11932063 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine 1 mg/cc plus normal saline
Number of subjects: 166
Study 9729942 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen-alginate dressing
Number of subjects: 75
Study 9729942 — intervention group
Group type: COMPARATOR
Intervention: Gauze dressing (control)
Number of subjects: 75
Study 8154643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g every 8 h)
Number of subjects: 696
Study 8154643 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (12 to 18 g/d in 4 to 6 divided doses) plus Tobramycin (1.7 to 2.0 mg/kg body weight every 8 h)
Number of subjects: 696
Study 8154643 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin plus Tobramycin
Number of subjects: 696
Study 8154643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 696
Study 2830091 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg twice a day
Number of subjects: 12
Study 31832821 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate (1.4 mg/m2 on days 1 and 8 every 21 days)
Number of subjects: 110
Study 31832821 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (25 mg/m2 on days 1, 8, and 15 every 21 days)
Number of subjects: 110
Study 30082420 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived threat manipulation in a controlled laboratory setting (Experiment I)
Number of subjects: 0
Study 30082420 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural variation of perceived threat in firefighters on duty (Experiment II)
Number of subjects: 0
Study 27385739 — intervention group
Group type: EXPERIMENTAL
Intervention: High elaboration (thoughtful consideration)
Number of subjects: 0
Study 27385739 — intervention group
Group type: COMPARATOR
Intervention: Low elaboration (nonthoughtful consideration)
Number of subjects: 0
Study 27385739 — intervention group
Group type: EXPERIMENTAL
Intervention: Second message (opposed to the first)
Number of subjects: 0
Study 24568949 — intervention group
Group type: EXPERIMENTAL
Intervention: True auriculopressure (TAP)
Number of subjects: 265
Study 24568949 — intervention group
Group type: COMPARATOR
Intervention: Placebo auriculopressure (PAP)
Number of subjects: 265
Study 22572202 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 18201
Study 22572202 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (target INR 2.0-3.0)
Number of subjects: 18201
Study 22572202 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban vs Warfarin
Number of subjects: 18201
Study 20934155 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent administration of tisokinase (960,000 IU)
Number of subjects: 60
Study 20934155 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous irrigation using pH-adjusted lactate Ringer's solution containing tisokinase (96 IU/mL) infused at 20 mL/hr for 48 hours
Number of subjects: 60
Study 20934155 — intervention group
Group type: COMPARATOR
Intervention: Control group treated only with baseline treatment
Number of subjects: 60
Study 17126565 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal primes with a short prime-target ISI interval (100 ms)
Number of subjects: 0
Study 17126565 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal primes with a long prime-target ISI interval (800 ms)
Number of subjects: 0
Study 16155135 — intervention group
Group type: EXPERIMENTAL
Intervention: PGLA-coated coils
Number of subjects: 51
Study 16155135 — intervention group
Group type: COMPARATOR
Intervention: Bare platinum coils
Number of subjects: 51
Study 12576372 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation service (ACS) monitoring
Number of subjects: 231
Study 12576372 — intervention group
Group type: COMPARATOR
Intervention: Primary care providers (PCPs) monitoring
Number of subjects: 231
Study 12576372 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS monitoring
Number of subjects: 231
Study 12576372 — intervention group
Group type: COMPARATOR
Intervention: PCP monitoring
Number of subjects: 231
Study 12576372 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who maintained their warfarin dose
Number of subjects: 231
Study 12576372 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who decreased their dose by 1 to 20%
Number of subjects: 231
Study 12576372 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who decreased their dose by 21 to 43%
Number of subjects: 231
Study 10536540 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index (BIS)
Number of subjects: 37
Study 10536540 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% Spectral Edge Frequency (SEF)
Number of subjects: 37
Study 10536540 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV)
Number of subjects: 37
Study 10536540 — intervention group
Group type: EXPERIMENTAL
Intervention: Approximate Entropy (ApEn)
Number of subjects: 37
Study 10536540 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS
Number of subjects: 37
Study 8542169 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms budesonide (single evening dose)
Number of subjects: 18
Study 8542169 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms budesonide (twice daily for 2 weeks)
Number of subjects: 18
Study 8542169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1466208 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin concentrate (AT group)
Number of subjects: 32
Study 1466208 — intervention group
Group type: COMPARATOR
Intervention: Non-antithrombin concentrate (non-AT group)
Number of subjects: 32
Study 6233335 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.1 mg/kg/day
Number of subjects: 150
Study 6233335 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 0.5 mg/kg/day
Number of subjects: 150
Study 6233335 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin 1.0 mg/kg/day
Number of subjects: 150
Study 30944226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hammock positioning (n = 13)
Number of subjects: 26
Study 30567583 — intervention group
Group type: EXPERIMENTAL
Intervention: Zika virus testing using ELISA
Number of subjects: 0
Study 30567583 — intervention group
Group type: EXPERIMENTAL
Intervention: Zika virus testing using PRNT
Number of subjects: 0
Study 27164459 — intervention group
Group type: EXPERIMENTAL
Intervention: 94 mL of prewarmed iopromide 240 mg I/mL at 8.3 mL/s
Number of subjects: 200
Study 27164459 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mL of 300 mg I/mL at 6.7 mL/s
Number of subjects: 200
Study 27164459 — intervention group
Group type: EXPERIMENTAL
Intervention: 61 mL of 370 mg I/mL at 5.4 mL/s
Number of subjects: 200
Study 27164459 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 200
Study 24647852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral release procedure
Number of subjects: 33
Study 24647852 — intervention group
Group type: COMPARATOR
Intervention: Outpatient clinic imaging
Number of subjects: 33
Study 24647852 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (before and after lateral release)
Number of subjects: 33
Study 22523335 — intervention group
Group type: COMPARATOR
Intervention: Bradykinin infusion in the left leg (Study I)
Number of subjects: 20
Study 22523335 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemia (Study II)
Number of subjects: 20
Study 22523335 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin during euglycemic hyperinsulinemia (Lean group)
Number of subjects: 20
Study 22523335 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin during euglycemic hyperinsulinemia (Obese group)
Number of subjects: 20
Study 19692213 — intervention group
Group type: EXPERIMENTAL
Intervention: High MUFA diet
Number of subjects: 60
Study 19692213 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 60
Study 19692213 — intervention group
Group type: COMPARATOR
Intervention: High SFA diet
Number of subjects: 60
Study 17660604 — intervention group
Group type: EXPERIMENTAL
Intervention: Depakin-chrono, 500 mg tablets, daily dose varied 250-1500 mg/day
Number of subjects: 20